NCI advisors approve recompetition of $62 million phase II contracts program.
Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.
Advisors approve set-aside for alternative medicine “best case series.”
HHS bans tobacco from its campuses, opens national quitline, 1-800-QUITNOW.
Two founding cancer center directors step down: Harold Moses at Vanderbilt-Ingram and Charles Coltman at CTRC.
Funding opportunities listed.
November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.
Trending Stories
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit - Cyber-iconoclast Vinay Prasad named head of FDA’s CBER
An oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies - George Weiner: Cancer centers are special, as are site visits in CCSG review
- Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- $180M in NCI grants have been terminated by Trump administration, systematic review finds
